InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,150.00
(
-0.43%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.14
(
-0.22%
)
Bitcoin
67,683.63
(
-0.35%
)
Post# of 251927
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4545
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: jbog post# 191727

Wednesday, 05/27/2015 12:00:20 PM

Wednesday, May 27, 2015 12:00:20 PM

Post# of 251927
From the release it sounds like the first trial only enrolled non-ciorrhotics w high baseline VL, so the 95% SVR has to be taken in that context. Not sure about the randomized portion, but the 98% here helps compete w GILD (GILD had 100% SVR in a somewhat smaller trial)
I don't think the cirrhotic data is competitive w GILD though
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up